Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA1 Protein | 7 | 2020 | 25 | 1.500 |
Why?
|
| Gestational Trophoblastic Disease | 2 | 2020 | 6 | 1.200 |
Why?
|
| Receptors, Lysophosphatidic Acid | 2 | 2025 | 15 | 1.000 |
Why?
|
| Lysophospholipids | 2 | 2025 | 51 | 0.970 |
Why?
|
| RNA, Long Noncoding | 2 | 2024 | 32 | 0.960 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2025 | 19 | 0.950 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 25 | 0.940 |
Why?
|
| Naphthoquinones | 3 | 2020 | 11 | 0.920 |
Why?
|
| Signal Transduction | 5 | 2025 | 1455 | 0.880 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2020 | 8 | 0.810 |
Why?
|
| Neoplasms | 2 | 2025 | 857 | 0.770 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 292 | 0.700 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 51 | 0.640 |
Why?
|
| Placenta | 1 | 2020 | 78 | 0.630 |
Why?
|
| Antiviral Agents | 1 | 2020 | 114 | 0.630 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 472 | 0.610 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 92 | 0.600 |
Why?
|
| DNA Methylation | 1 | 2020 | 152 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 164 | 0.590 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 344 | 0.590 |
Why?
|
| Mutation | 3 | 2020 | 864 | 0.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 465 | 0.510 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 170 | 0.370 |
Why?
|
| Cell Proliferation | 4 | 2024 | 817 | 0.360 |
Why?
|
| Apoptosis | 3 | 2020 | 777 | 0.320 |
Why?
|
| Prognosis | 4 | 2020 | 807 | 0.310 |
Why?
|
| Humans | 16 | 2025 | 28585 | 0.290 |
Why?
|
| BRCA2 Protein | 2 | 2020 | 20 | 0.290 |
Why?
|
| MicroRNAs | 2 | 2024 | 301 | 0.270 |
Why?
|
| Animals | 6 | 2025 | 10583 | 0.260 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 36 | 0.250 |
Why?
|
| Pregnancy | 2 | 2020 | 1219 | 0.220 |
Why?
|
| Cell Movement | 1 | 2024 | 373 | 0.190 |
Why?
|
| Cell Nucleus | 1 | 2022 | 138 | 0.180 |
Why?
|
| Female | 9 | 2024 | 15472 | 0.180 |
Why?
|
| Homeostasis | 1 | 2022 | 118 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 164 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 148 | 0.170 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 1341 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 27 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2018 | 115 | 0.170 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2020 | 2 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2020 | 39 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2020 | 81 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2020 | 68 | 0.160 |
Why?
|
| Chorionic Gonadotropin | 1 | 2019 | 22 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 314 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 111 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 196 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 15 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2020 | 893 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 141 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 595 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 120 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 410 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 681 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 27 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 48 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 50 | 0.120 |
Why?
|
| Proteomics | 1 | 2017 | 192 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 54 | 0.120 |
Why?
|
| Incidence | 1 | 2017 | 568 | 0.120 |
Why?
|
| Nitric Oxide | 1 | 2016 | 152 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 282 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 275 | 0.090 |
Why?
|
| DNA Repair | 2 | 2020 | 82 | 0.070 |
Why?
|
| Adult | 1 | 2020 | 7922 | 0.070 |
Why?
|
| Mice | 3 | 2024 | 4735 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2024 | 332 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 183 | 0.050 |
Why?
|
| Breast | 1 | 2020 | 52 | 0.040 |
Why?
|
| Recombinational DNA Repair | 1 | 2019 | 7 | 0.040 |
Why?
|
| DNA Damage | 1 | 2020 | 151 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2019 | 61 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 214 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2018 | 55 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2018 | 10 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 509 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 453 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 160 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 78 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 288 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 118 | 0.030 |
Why?
|
| Prostate | 1 | 2016 | 52 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 366 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 862 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 671 | 0.020 |
Why?
|
| Male | 1 | 2016 | 13772 | 0.010 |
Why?
|